Construction and characterization of a single-chain antibody fragment derived from thymus of a patient with myasthenia gravis

Autoimmunity

Volumn 35, Issue 2, 2002, Pages 125-133

  Stassen, Maurice H W ^a   Schillberg, Stefan ^c   Fischer, Rainer ^b   De Baets, Marc H ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c NONE

Author keywords

Acetylcholine receptor; Myasthenia gravis; Single chain variable fragment (scFv); Thymus

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; MAIN IMMUNOGENIC REGION MONOCLONAL ANTIBODY 35; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIGENIC MODULATION; ARTICLE; BINDING AFFINITY; BINDING SITE; COMPETITIVE INHIBITION; COMPLEMENT ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; ISOLATED ORGAN; MONKEY; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NONHUMAN; PHAGE DISPLAY; POLYMERASE CHAIN REACTION; PROTEIN BINDING; RADIOIMMUNOPRECIPITATION; SERUM; THYMUS;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS; HAPLORHINI; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MOLECULAR SEQUENCE DATA; MUSCLES; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC; THYMUS GLAND;

EID: 0036085232     PISSN: 08916934     EISSN: None     Source Type: Journal    
DOI: 10.1080/08916930290016646     Document Type: Article

References (55)

1. Myasthenia gravis
2. Myasthenia gravis: An autoimmune response against the acetylcholine receptor
3. Myasthenia gravis
4. Experimental autoimmune myasthenia gravis and myasthenia gravis: Biochemical and immunochemical aspects
5. Myasthenia gravis: Passive transfer from man to mouse
6. Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor
7. The nicotinic acetylcholine receptor: Structure and autoimmune pathology
8. Biochemical properties of acetylcholine receptor subunits from Torpedo californica
9. Acetylcholine receptor: Complex of homologous subunits
10. Localization of subunits within the acetylcholine receptor by electron image analysis of tubular crystals from Torpedo marmorata
11. Mapping of the main immunogenic region and toxin binding site of the nicotinic acetylcholine receptor
12. Monoclonal antibodies to the main immunogenic region of the nicotinic acetylcholine receptor binds to residues 61 - 76 of the α-subunit
13. Localization of the main immunogenic region of the human muscle acetylcholine receptor to residues 67 - 76 of the α-subunit
14. Monoclonal antibodies used to probe acetylcholine receptor structure: Localization of the main immunogenic region and detection of similarities between subunits
15. Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies
16. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor
17. Myasthenia gravis induced by monoclonal antibodies to acetylcholine receptor
18. Sequence analysis of anti-AChR antibodies in experimental autoimmune myasthenia gravis
19. Decrease in acetylcholine-receptor content of human myotube cultures mediated by monoclonal antibodies to α,β and γ subunits
20. The treatment of passively transferred experimental myasthenia with anti-idiotypic antibodies
21. Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor
22. T cell reactivity to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis
23. B cell responses to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis
24. Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences
25. Antigen specific modulation of experimental myasthenia gravis: Nasal tolerization with recombinant fragments of the human acetylcholine receptor a subunit
26. Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: Identification of regulatory cells
27. Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies
28. Diverse Fab specific for acetylcholine receptor epitopes from a myasthenia gravis thymus combinatoral library
29. Fab fragments of monoclonal antibodies protect the human acetylcholine receptor against degradation caused by myasthenic sera
30. Prevention of passively transferred experimental autoimmune myasthenia gravis by Fab fragments of monoclonal antibodies directed against the main immunogenic region of the acetylcholine receptor
31. Construction and characterization of a humanized single chain Fv antibody fragment against the main immunogenic region of the acetylcholine receptor
32. Bacterial expression of single-chain Fv fragment which efficiently protects the acetylcholine receptor against antigenic modulation caused by myasthenic antibodies
33. High affinity single-chain antibody fragments protecting the human nicotinic actylcholine receptor
34. Characterization of human variable domain antibody fragments against the U1 RNA-associated A protein, selected from a synthetic and a patient-derived combinatoral V gene library
35. Changes in anti-U1 RNA antibody levels correlate with disease activity in patients with systemic lupus erythematosus overlap syndrome
36. A muscle acetylcholine receptor is expressed in the human cerebellar medulloblastoma cell line TE671
37. Monoclonal antibodies against the main immunogenic region of the acetylcholine receptor: Mapping on the intact molecule
38. Precise epitope mapping of monoclonal antibodies to the cytoplasmic site of the acetylcholine α-subunit. Dissecting a potentially myasthenogenic epitope
39. Relative position of the hexahistidine tag effects binding properties of a tumor-associated single-chain Fv construct
40. A single chain Fv specific against Western equine encephalitis virus
41. Properties of polyclonal, monoclonal, and recombinant antibodies recognizing the organophosphorus pesticide chlorpyrifos-ethyl
42. Expression and characterization of human rheumatoid factor single-chain Fv
43. Characterization of four nucleic acid-binding single-chain Fv fragments by direct and competitive solid-phase radioimmunoassays
44. Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography
45. Construction and characterization of a novel recombinant single-chain variable fragment antibody against Western equine encephalitis virus
46. Construction and characterization of a quadruplex DNA selective single-chain autoantibody from a viable motheaten mouse hybridoma with homology to telomeric DNA binding proteins
47. Phage display of a cellulose binding domain from clostridium thermocellum and its application as a tool for antibody engineering
48. Molecular cloning, expression, and characterization of a functional single-chain Fv antibody to the mycotoxin zearalenone
49. Influences of amino acid sequences in FR1 region on binding activity of the scFv and Fab of an antibody to human gastric cancer cells
50. Identification of residues that stabilize the single-chain Fv of monoclonal antibodies B3
51. Humanization of mouse ONS-M21 antibody with the aid of hybrid variable regions
52. The I binding specificity of human VH 4-34 (VH 4-21) encoded antibodies is determined by both VH framework region 1 and complementarity determining region 3
53. Absolute conservation of residue 6 of immunoglobulion heavy chain variable regions of class IIA is required for correct folding
54. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties